NOVADIGM THERAPEUTICS
NovaDigm Therapeutics develops vaccines to protect patients from fungal and bacterial infections. Its products include NDV-3, a vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by fungal and bacterial pathogens; and Als3, an antigen vaccine, which provides protection against systemic and mucosal candidal infections. It was founded in 2005 and headquartered in Grand Forks, North Dakota.
NOVADIGM THERAPEUTICS
Industry:
Biotechnology Health Care Medical Device Therapeutics
Founded:
2005-01-01
Address:
Grand Forks, North Dakota, United States
Country:
United States
Website Url:
http://www.novadigm.net
Total Employee:
11+
Status:
Active
Contact:
7013357121
Email Addresses:
[email protected]
Total Funding:
64.82 M USD
Technology used in webpage:
Viewport Meta Google Analytics Mobile Non Scaleable Content AJAX Libraries API Pound Sterling Google Analytics Classic Japanese Yen
Current Advisors List
Current Employees Featured
Founder
Investors List
U.S. Department of Defense
U.S. Department of Defense investment in Grant - NovaDigm Therapeutics
RMI Partners
RMI Partners investment in Convertible Note - NovaDigm Therapeutics
RMI Partners
RMI Partners investment in Series B - NovaDigm Therapeutics
Domain Associates
Domain Associates investment in Series B - NovaDigm Therapeutics
RMI Partners
RMI Partners investment in Series B - NovaDigm Therapeutics
Domain Associates
Domain Associates investment in Series A - NovaDigm Therapeutics
Official Site Inspections
http://www.novadigm.net Semrush global rank: 5.92 M Semrush visits lastest month: 1.39 K
- Host name: a67c48129651a0940.awsglobalaccelerator.com
- IP address: 76.223.67.189
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "NovaDigm Therapeutics" on Search Engine
NovaDigm Therapeutics
NovaDigm Therapeutics. NovaDigm is developing innovative immunotherapeutics and preventative vaccines to protect patients from fungal and bacterial disease, which can be …See details»
NovaDigm Therapeutics - Crunchbase Company Profile & Funding
Therapeutics. Headquarters Regions Midwestern US. Founded Date 2005. Founders Brad Spellberg, John E. Edwards. Operating Status Active. Last Funding Type Grant. Legal …See details»
Novadigm Therapeutics Company Profile 2024: Valuation, …
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most. Information on valuation, funding, cap tables, …See details»
Board of Directors - About Us - NovaDigm
Brady has more than 18 years of pharmaceutical clinical and business development experience and is currently president and CEO of Aldeyra Therapeutics. Prior to joining …See details»
NovaDigm Therapeutics Company Profile - Craft
Private. Status. Active. Founded. 2005. site. http://www.novadigm.net. Cybersecurity rating. Sectors. Healthcare. biotech. drug development. pharma. Key People. R. Gordon …See details»
NovaDigm Therapeutics - Products, Competitors, Financials, …
NovaDigm Therapeutics is a biotechnology company focused on developing immunotherapeutics and preventative vaccines for fungal and bacterial diseases. Their …See details»
Safety, immunogenicity, and efficacy of NDV-3A against
May 27, 2021 Safety, immunogenicity, and efficacy of NDV-3A against Staphylococcus aureus colonization: A phase 2 vaccine trial among US Army Infantry trainees. Vaccine. …See details»
NovaDigm Therapeutics - Funding, Financials, Valuation & Investors
NovaDigm Therapeutics develops vaccines that protect patients from contracting fungal and bacterial infections.See details»
Novadigm Therapeutics, Inc. Company Profile | Brookline, MA ...
Overview. Company Description: Key Principal: Michael Cooke See more contacts. Industry: Scientific Research and Development Services , Professional, Scientific, and …See details»
NovaDigm Therapeutics Raises $4M - socaltech.com
Jul 30, 2008 Torrance-based NovaDigm Therapeutics, a stealth biomedical firm developing vaccines and therapeutics for the treatment of infections, has quietly raised …See details»
NovaDigm Therapeutics - Contacts, Employees, Board Members, …
NovaDigm Therapeutics develops vaccines that protect patients from contracting fungal and bacterial infections.See details»
Novadigm Therapeutics | VentureRadar
Site: http://www.novadigm.net. NovaDigm is developing innovative immunotherapeutics and preventative vaccines to protect patients from fungal and …See details»
NovaDigm Therapeutics, Inc. - Drug pipelines, Patents, Clinical …
Apr 2, 2024 Explore NovaDigm Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, and 1 literature, Disease Domain:Infectious …See details»
NovaDigm Therapeutics Strengthens - Business Wire
Jun 10, 2014 GRAND FORKS, N.D.-- ( BUSINESS WIRE )-- NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today …See details»
PNAS
PNASSee details»
NDV-3, a recombinant alum-adjuvanted vaccine for Candida and …
Dec 14, 2012 1 NovaDigm Therapeutics, Inc., Grand Forks, ND 58202, USA. PMID: 23099329. PMCID: PMC3513491. DOI: 10.1016/j.vaccine.2012.10.038. Abstract.See details»
NovaDigm Therapeutics, Inc. | LinkedIn
About us. site. http://novadigmtherapeutics.com. Industry. Biotechnology. Company size. 11-50 employees. Headquarters. Grand Forks, North Dakota. Locations. Primary. …See details»
Organization | NovaDigm Therapeutics, Inc. - CDEK
Organization Overview. First Clinical Trial. 2011 NCT01273922. First Marketed Drug. None First NDA Approval. None Last Known Activity ... NovaDigm Therapeutics, Inc. Active …See details»
NovaDigm Therapeutics | EquityNet
Company Overview. NovaDigm Therapeutics, Inc. develops vaccines to protect patients from fungal and bacterial infections. Its products include NDV-3, a vaccine to …See details»
Candida vaccine Sap2 - NovaDigm Therapeutics - AdisInsight
Jul 16, 2016 NovaDigm Therapeutics is developing a therapeutic candida vaccine, based on the a recombinant Sap2 antigen, for the treatment of chronic recurrent …See details»